Search
Menu
Home
HTB
2005
January
31
HTB
31 January 2005
Contents
Editorial
Volume 6 Number 1 December 2004/January 2005
Treatment alerts
Important new clinical data: potential early virologic failure associated with the combination antiretroviral regimen of tenofovir disoproxil fumarate, didanosine, and either efavirenz or nevirapine in HIV treatment-naive patients with high baseline viral loads
Conference reports
6th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV (IWADRLH) 26-28 October 2004, Washington
Nucleoside analogue-related mitochondrial toxicity and link to lipoatrophy: effect of non-thymidine analogues abacavir and tenofovir
Nucleosides reduce PPAR-gamma: a role for rosiglitazone without thymidine analogues?
Potential for uridine to treat mitochondrial toxicity: still only in vitro data
25% patients take Kaletra on an empty stomach: dietary advice often missed at ‘centre of excellence’
rHGH reduces central fat accumulation in adolescent lipodystrophy
Weight loss is associated with elevated PBMC proviral DNA levels
Coronary artery bypass graft is safe in HIV-positive patients but shows higher risk of longer term events
Endothelial dysfunction similar in ARV-experienced and -naive patients
Pravastatin improves lipid profiles but not endothelial function
Indinavir impairs endothelial function without insulin resistance
Treatment interruptions improve lipids within four weeks: IL-2 has no metabolic effect
Improvement of lipids following switch to tenofovir
HCV coinfection linked to discontinuing ART due to toxicity
Restorative treatments for HIV-associated lipoatrophy
44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 30 October-2 November 2004, Washington
Tipranavir in treatment experienced patients: results from RESIST-1
Reverset: first data in patients with nucleoside resistance
Poor response with tenofovir and ddI backbone causes early study termination
HTB RSS
Current issues
March 2024
February 2024
January 2024
Back issues
Special report
Modelling study challenges links between gender and PrEP: event-based dosing and easier daily dosing should work for all
12 February 2024
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage